In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer
Merck’s immuno-oncology team has become expert at pressing an early advantage.
The Keytruda company, which recently trounced Bristol-Myers in their rivalry on lung cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
